Creatine supplementation in COPD

Creatine supplementation as an exercise performance enhancer for patients with COPD? An idea to run with

T L Griffiths, D Proud

Creatine supplementation may enhance pulmonary rehabilitation in patients with COPD, but larger trials are needed

Multidisciplinary pulmonary rehabilitation now has an established place in the management of chronic disabling respiratory diseases, particularly chronic obstructive pulmonary disease (COPD). Rehabilitation is being taken up widely on the strength of the accumulated evidence. While the effectiveness of rehabilitation is accepted, there is still considerable interest in refining and researching the individual modalities of treatment that make up the multidisciplinary intervention.

Exercise training is a key component of an effective pulmonary rehabilitation programme. In recent years a number of approaches have been taken in an effort to enhance the effectiveness of physical training, particularly for more severely disabled patients who may have reduced muscle bulk and whose baseline exercise capacity is particularly low. Broadly, strategies have either concentrated on acute interventions that enable subjects to train at higher intensity or have focused on altering underlying skeletal muscle functioning. An example of the former approach is the inclusion of oxygen supplementation during training in patients with hypoxaemia. Acute oxygen supplementation does enhance exercise performance and allows a higher work output for training. However, its use in training programmes has not been found to improve the overall outcomes of rehabilitation. Taking the alternative approach, attempts to restore muscle function have been made by applying muscle-like techniques used for performance enhancement in sport and other areas of medicine. These interventions have included nutritional supplementation, the use of anabolic steroids, and the use of growth hormone. These kinds of intervention do increase muscle bulk but do not tend to produce beneficial gains in terms of whole body exercise and patient based outcomes in patients disabled by COPD and low muscle mass.

The underlying causes of the reduction in muscle mass in patients with COPD are likely to be heterogeneous and complex. They include imbalance in caloric intake and expenditure, disuse, the systemic effects of glucocorticoid steroid treatment, low circulating androgen levels, and systemic inflammation. The high prevalence of low muscle mass in patients with COPD is now recognised, as is the adverse impact of malnutrition in terms of disability, health service usage, and mortality.

Therapeutic use of creatine supplementation

Set alongside these developments, there has been a growing interest in recent years in the potential for creatine supplementation to benefit various patient groups. When used as a dietary supplement, creatine monohydrate increases the availability of phosphocreatine in skeletal muscle. Phosphocreatine contributes a store of high energy phosphate bonds available at the onset of exercise. Following dephosphorylation, the creatine then becomes available for subsequent regeneration of phosphocreatine. A further effect of creatine is to increase fat-free mass by mechanisms that are not fully understood but which may have to do with muscle water content. In view of these effects, creatine monohydrate has become widely used to enhance athletic exercise performance, particularly in activities characterised by short bursts of activity rather than sustained effort. As with other interventions, creatine supplementation has also made the jump to application in disease states.

In a recent review of therapeutic creatine supplementation, Terjung et al. highlighted a number of conditions including neuromuscular diseases where possible benefits to exercise capacity, muscle strength, and muscle mass may be seen. Mathews et al. reported potential neuroprotective effects related to oxidative stress in an animal model of Huntington’s disease. The potential for improved cardiac function and skeletal muscle performance in congestive heart failure with creatine supplementation has also been studied. The direct effect of creatine supplementation on lung function, enzymatic activity, and muscle strength in patients with cystic fibrosis has recently been reported in a pilot study. The authors concluded that, although no change in lung function or enzymatic activity in respiratory epithelial cells was evident, improvements in muscle strength and general wellbeing were seen. A number of studies have addressed the potential benefits of creatine supplementation in the elderly. Although most studies have failed to find significant effects, a more recent study identified significant increases in muscle strength, fat free mass, and total body mass when creatine supplementation was offered in combination with resistance training.

Creatine supplementation in COPD

With this background, it is perhaps surprising that the effect of creatine supplementation on muscle mass and muscle function in patients with COPD has been very little researched. This situation begins to be remedied by a paper in this issue of Thorax.

Fuld and colleagues report a randomised controlled trial of creatine monohydrate supplementation as an adjunct to exercise training in patients with moderately severe COPD. Their subjects received a standard 2 week loading regimen followed by a maintenance dose of creatine monohydrate or placebo in a randomised double blind fashion. After the loading phase, subjects participated in an exercise training programme of two sessions per week for 16 weeks. Training sessions included mobility and strength training together with 20 minutes of endurance training on a static bike. The primary outcome variable was 10 metre incremental shuttle walk distance. Secondary outcomes were body composition, muscle strength, and cardiopulmonary responses to incremental exercise testing and disease specific health status. Although this was essentially a negative study with respect to its primary outcome variable, the authors present intriguing secondary outcome data. Firstly, fat free mass increased on average by 1.1 kg in the creatine supplemented group, significantly more than in the placebo group after the loading phase. At the same time, significant benefits in indices of upper and lower limb muscle functioning were seen in the creatine group compared with the
placebo group. While the findings for isolated muscle work were consistent, no discernible trend or significance for between-group differences was seen in response to whole body exercise, either on the cycle ergometer or corridor walking tests. Thus, once again, apparent benefits at a muscle level were not translated into improvements in the integrated response to whole body exercise. Outcomes following exercise training while continuing creatine supplementation were compared with the pre-creatine baseline. Improvements were seen in terms of fat-free mass and limb muscle functioning following training in both groups, but the gap between the creatine supplemented and placebo groups widened. Again, indices of the response to cycling and walking exercise changed inconsistently. Shuttle walking tests showed significant improvements after training but without appreciable differences between groups. Perhaps the most tantalising finding of the study is the significantly greater improvement seen in the creatine supplemented group in St George’s Respiratory Questionnaire (SGRQ) score after training. There are certainly problems in interpreting the results from this questionnaire in groups of patients as small as 11. However, the suggestion that creatine supplementation can lead to improvements in health status while improving individual muscle function independently of any effect on walking capacity is of great interest.

IMPLICATIONS OF STUDY

Everyday life is a series of varying transitions from one level of exercise to another and does not often approximate to the conditions of an incremental or endurance shuttle walk test. The physiological effect of creatine is postulated to be as a result of increased ready availability of high energy phosphate bonds within the muscles. These can be used to sustain work rate increases anaerobically until increased oxygen delivery to the muscle can sustain oxidative metabolism and eventually repay the oxygen deficit. The effect of creatine supplementation might therefore support the bioenergetic response to changes in work output. It might be that improving the “flexibility” of response to short step changes in work output is what is driving improvements in health status in this study. While this is an attractive hypothesis, there is a problem with the confident interpretation of the present study. Exercise training was accompanied by a surprising decrement in SGRQ scores in the non-supplemented group, whereas clinically important improvements were seen in the creatine supplemented group. In a group of patients prone to exacerbation and unexpected changes in health, much larger numbers of subjects would be needed to provide results confidently applicable to the generality of COPD patients. Additionally, this study begs the question as to whether similar effects would be seen in the context of multidisciplinary rehabilitation rather than pure exercise training.

Thus, as many questions are raised as are answered in the study reported by Fulld and colleagues. However, there is a prime facie case to answer as to whether creatine supplementation will indeed enhance the outcome of pulmonary rehabilitation in its more usual multidisciplinary format. The challenge now is to undertake a large randomised controlled trial, powered to detect clinically important differences in health status, to test this hypothesis. We will then be able to determine the potential usefulness of creatine supplementation in the context of multidisciplinary pulmonary rehabilitation for patients disabled by COPD.


Authors’ affiliations
T L Griffiths, Wales College of Medicine, Cardiff University, Llandough Hospital, Penarth CF64 2XX, UK
D Proud, Pulmonary Rehabilitation Unit, Llandough Hospital, Penarth CF64 2XX, UK

Correspondence to: Dr T L Griffiths, Wales College of Medicine, Cardiff University, Llandough Hospital, Penarth, CF64 2XX, UK; griffithsl@cf.ac.uk

No conflicts of interest to declare

REFERENCES

Smoking and tuberculosis

Smoking and tuberculosis: a chance or causal association?

G H Bothamley

Possible explanations for the association between smoking and tuberculosis

In 1956 Doll and Hill\(^1\) wrote that “the relationship between smoking and mortality from pulmonary tuberculosis is distinct, but with a disease so influenced by social factors more precise data are needed to justify a direct cause and effect hypothesis”.

The essential risk factors for human tuberculosis are (1) the tubercle bacillus, (2) a susceptible host, and (3) an environment which allows the tubercle bacilli to survive transit from one host to the next. All other risk factors are subsumed under these headings. If smoking is a risk factor for tuberculosis, then it must act by increasing the susceptibility of the human host or the probability of transmission by encouraging infectious individuals to cough (this requires smoking to be a social as much as an individual pursuit). If the association between smoking and tuberculosis is more apparent than real, then smoking may be a pointer to other risk factors. These include social class—itself a marker for overcrowding, poor ventilation and rooms with no natural light as well as poor nutrition—general ill health and, increasingly, HIV infection with prostitution and intravenous drug use.

TUBERCULIN SENSITIVITY AND SMOKING

Tuberculous infection and tuberculosis as a disease are entirely different states. The former is commonly characterised by tuberculin reactivity (despite the known problem of exposure to non-tuberculous mycobacteria and the cross reactivity of the mixture of antigens\(^2\)). Approximately one third of the world’s population may be infected with the tubercle bacillus, but only eight million population may be infected with the tubercle bacillus, but only eight million population may be infected with the tubercle bacillus, but only eight million population may be infected with the tubercle bacillus, but only eight million population may be infected with the tubercle bacillus, but only eight million population may be infected with the tubercle bacillus, but only eight million population may be infected with the tubercle bacillus, but only eight million population may be infected with the tubercle bacillus.

In Norway, linear regression analysis associated smoking and male sex with greater tuberculin reactivity.\(^3\) In a study in Kuwait tuberculin reactivity was greater in smokers, and univariate analysis of variance showed a dose-response to pack-years in healthy controls but not in patients with tuberculosis.\(^4\) None of these studies accounted for socioeconomic status and its possible confounding effect on smoking and tuberculosis.

In this issue of Thorax a study by Den Boon et al\(^5\) in a socially homogeneous group again shows that tuberculin reactivity can be related to smoking, especially if this constituted more than 15 pack-years. More interestingly, a prospective study in the United States examined whether smokers were more likely to have developed a positive tuberculin reaction while in prison.\(^6\) Only those who had smoked for more than 15 years were more likely to show tuberculin conversion (relative risk 2.12, 95% confidence interval 1.03 to 4.36). The authors concluded that the cumulative effect of prolonged smoking was more significant than the number of cigarettes smoked in increasing the likelihood of infection by Mycobacterium tuberculosis in prison. The broad confidence intervals, with the lower figure giving an attributable risk of <3% to smoking for tuberculin conversion, recommend a further study with greater power and with an assessment of the duration of imprisonment. Exposure to M avium-intracellulare is common in the southern United States and may affect tuberculin conversion. Concurrent HIV infection is more common in those aged 20–35 years and might also confound tuberculin sensitivity. A future prospective study would need to examine the social behaviour of chronic smokers and the likelihood of the index case being within those who have smoked for >15 years.

The evidence to support a direct effect of smoking on tuberculin reactivity is therefore poor.

SMOKING AND TUBERCULOSIS

As already mentioned, tuberculosis as a disease is very different from tuberculous infection, defined by a positive tuberculin response. Several studies, beginning in 1956, have linked smoking with tuberculosis (reviewed by Maurya et al\(^7\)). As in a more recent study,\(^8\) the possible confounding of socioeconomic factors with both smoking and tuberculosis has only occasionally been examined.\(^9\) Yu et al\(^10\) used binomial regression to propose that heavy smoking was associated with pulmonary tuberculosis, although both were associated with male sex and increasing age. A case-control study matching street based postcode, sex, date of birth, and ethnic origin in Liverpool suggested that smoking for >30 years was associated with the development of all forms of tuberculosis,\(^11\) but this was not significant when corrected for the number of factors examined. Prospective evaluation of 42 655 individuals registered with the Elderly Health Service in Hong Kong noted that pulmonary tuberculosis was more common in current smokers than in ex-smokers, and both were more common than in never smokers. Cox proportional hazards analysis accounted for 18 potential confounding factors including alcohol and several relating to socioeconomic status. There was also a dose-response relationship in current smokers for the development of pulmonary tuberculosis. A small study of contacts of sputum smear positive tuberculosis compared 46 adult patients with culture positive pulmonary tuberculosis and 46 tuberculosis positive subjects without active tuberculosis.\(^12\) Adjusting the odds ratios for age, sex, and socioeconomic status demonstrated a dose-response relationship between the number of cigarettes smoked and the risk of active pulmonary tuberculosis. A similar study from the same group compared children in contact with tuberculosis who later developed the disease with those who remained well during the period of study despite a positive tuberculin skin test.\(^13\) Passive smoking, as assessed from the smoking history of the adult case and from urinary cotinine levels, was associated with a risk of developing pulmonary tuberculosis (~80% primary complex disease). One would have to postulate that the infectious load, related to coughing behaviour of the smoking adult and using cotinine levels.
as a marker of proximity of the adult, was significant if passive smoking itself was not the significant factor in the development of active tuberculosis. The data are consistent with the hypotheses that both a long duration of smoking and current smoking might be related to the development of active pulmonary tuberculosis.

**EFFECTS OF SMOKING AND THE IMMUNE RESPONSE IN THE LUNG**

The alveolar macrophage is probably the first cell to ingest a tubercle bacillus following infection. These cells suppress the local immune response in order to preserve lung architecture. Silicosis is associated with an increased incidence of tuberculosis, suggesting that proper function of these cells is protective. Smoking impairs the phagocytic function of alveolar macrophages. Both smoking and tuberculosis induce apoptosis of these cells. However, smoking quadruples the number of macrophages that can be harvested by bronchial lavage. Cigarette smoke activates alveolar macrophages to produce a local inflammatory response, but nicotine suppresses the antigen presentation function to develop a specific immune response. Chronic exposure to cigarette smoke reduces expression of surface proteins related to antigen presentation by pulmonary macrophages. Others have suggested that human alveolar type II pneumocytes may be the first port of call for the tubercle bacillus,27 and there may be factors from this cell that might inhibit T cell proliferation but permit T cell activation and cytokine secretion.

**CONCLUSION**

The association of smoking with pulmonary tuberculosis might be explained by a reduced specific immunity and possibly enhanced non-specific inflammatory response. Such a model would predict that smoking during exposure to tubercle bacilli is less likely to induce delayed hypersensitivity but more likely to produce disease. If correct, any increase in tuberculin sensitivity associated with smoking would have to be explained by social behaviour rather than the host response.


Correspondence to: Dr G H Bothamley, NE London TB Network, Homerton University Hospital, London E9 6SR, UK; graham.bothamley@homerton.nhs.uk

**REFERENCES**

5 Woz J, Chau HS, Hazlett CB, et al. Tuberculosis among elderly Chinese in residential homes: tuberculin reactivity and estimated prevalence
27 Bermudez LE, Goodman J, Mycobacterium tuberculosis evades and replicates within type II alveolar cells. Infect Immun 1996;64:1400–0
Is the neutrophil the key effector cell in severe asthma?

A V Kamath, I D Pavord, P R Ruparelia, E R Chivers

The importance of the neutrophil as the dominant inflammatory cell in many of the non-atopic and more severe phenotypes of asthma is now clear

Eosinophilic inflammation has long been considered one of the most distinctive pathological hallmarks of asthma and features in many contemporary definitions of this disease. A plethora of studies published from the mid 1990s onwards have suggested, however, that airway eosinophilia is not a universal finding. This has fuelled debate that discrete pathological phenotypes of asthma may exist, with the neutrophil—rather than the eosinophil—dominating in certain circumstances. We present data that support the current hypothesis that the eosinophil is the key effector cell involved in the pathogenesis of asthma has run into trouble for several reasons: (1) eosinophilic inflammation is present in the airway lumen of only 50% of asthmatic subjects; (2) even intense eosinophilic inflammation, as occurs in eosinophilic bronchitis, fails to induce asthma; (3) many asthma exacerbations occur in the absence of airway eosinophilia; (4) specific anti-eosinophil strategies—for example, anti-IL-5 and IL-12—are poorly efficacious in vivo; and (5) eosinophil deficient mice have now been engineered and this modification has little impact on the airway pathology induced in response to ovalbumin sensitisation.

A strong association has now been established between neutrophilic inflammation of the airways and severe asthma, corticosteroid resistant asthma, nocturnal asthma, asthma in smokers, occupational asthma, and “sudden onset” fatal asthma. It is noteworthy that, in the study by Little and colleagues conducted in a group of 59 asthmatics, forced expiratory volume in 1 second (FEV₁) was inversely proportional to neutrophil numbers. These studies analysed neutrophil numbers in all airway compartments including the small airways and, where measured, neutrophil numbers correlated well with markers of neutrophil degranulation which implies that these cells are also activated. These findings are of particular importance given the disproportionate health costs associated with treating patients with severe disease.

These data set up a number of critical questions—namely:

- What are the principal drivers of neutrophil influx into asthmatic airways?
- Can any of the existing asthma treatments be implicated in airway neutrophilia?
- How do we quantify neutrophil trafficking in this disease?
- What are the most promising therapeutic options to inhibit this process?

It is now widely argued that certain physical triggers including viruses, lipopolysaccharides, and ozone may be more important inducers of airway neutrophilia than any primary immunological cause, and epithelial derived IL-8 again stands out as one of the most likely chemoattractants for neutrophils. While in severe disease eosinophils and neutrophils are usually found together, cross sectional studies suggest that neutrophils may have a greater role in the airway neutrophilia is further supported by experimental data obtained using an equine model of asthma where complete resolution of the neutrophilic airway response occurred over a matter of a few days following removal of the mouldy hay challenge. In this model the alveolar macrophages appeared to make a significant contribution to the clearance of apoptotic neutrophil corpses from within the airway lumen. Thus, if neutrophils do not reside within the asthmatic airways for protracted periods due to the presence of efficient natural clearance mechanisms, strategies designed to block influx—which presumably occurs at the post capillary venule level within the bronchial circulation—may be highly efficacious. Recent studies have revealed the pivotal role of the enzyme phosphoinositide 3-kinase in controlling neutrophil migration, activation and survival, and the discovery of neutrophil specific isoforms makes selective therapeutic targeting with conventional small molecular weight inhibitors a realistic prospect. Certainly, the introduction of a Δp85 phosphoinositide 3-kinase construct delivered using an HIV-TAT based protein delivery system in mice has a dramatic protective effect on ovalbumin induced airways inflammation.

Thus, while the role of the eosinophil in mediating airways inflammation in mild and moderate atopic asthma appears secure, the importance of the neutrophil as perhaps the dominant inflammatory cell in many of the non-atopic and more severe phenotypes of...
asthma is now equally clear. Corticosteroids are highly effective in promoting the resolution of eosinophilic inflammation but far less so in neutrophilic inflammation and, indeed, may even facilitate the arrival and survival of these cells in the airway wall.


**Authors’ affiliations**

A V Kamath, Department of Respiratory Medicine, Norfolk and Norwich University Hospital, Norwich, UK

I D Pavord, Institute of Lung Health, Glenfield Hospital, Leicester, UK

P R Ruparel, E R Chilvers, Respiratory Medicine Division, Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke’s Hospital and Papworth Hospitals, Cambridge, UK

Correspondence to: Professor E R Chilvers, University of Cambridge School of Clinical Medicine, Norfolk and Norwich University Hospital, Norwich, UK; erc24@cam.ac.uk

The work in the authors’ laboratories is supported by the Wellcome Trust, British Heart Foundation, Asthma UK, MRC, Papworth Hospital and the British Lung Foundation.

**REFERENCES**


